Abnova's VHH nanoBiTE™ service focuses on developing bispecific VHH antibodies without an Fc domain, ideal for immune and tumor cell redirecting, multiple epitope targeting, and novel immuno-oncology research. Their smaller molecular size enhances tissue penetration, making them suitable for hard-to-access areas like the tumor microenvironment. The absence of an Fc region prevents unwanted immune activation by avoiding Fc receptor binding, supporting precise mechanistic action. Engineered through the genetic fusion of two VHH domains via a flexible peptide linker, VHH nanoBiTE™ ensures robust antigen binding with reduced production complexity.

Workflow

nanoBiTE.jpg (202 KB)

 

 

Advantages

  • Small Size
  • Superior Stability
  • High Affinity and Specificity
  • Easy Conjugation
  • Enables Rapid Immune Cell Activation While Minimizing Systemic Exposure
  • Cost-Effectiveness and Scalable Production

 

 

Examples

Human PD-L1 x CD3e nanoBiTE™

Indirect ELISA

Service_Bispecific_Ab_data_1.jpg (113 KB)

 

 

Sandwich ELISA

Service_Bispecific_Ab_data_2.jpg (119 KB)

 

 

Flow cytometry

Service_Bispecific_Ab_data_3.jpg (145 KB)

 

 

  • TW : +886-2-8751-1888 / USA : +1(857) 639 0367 / Korea : +82-1670-5911.